Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2006

View Archived Issues

Speedel retains rights to SPP-200

MorphoSys signs second PER.C6 license agreement

TolerRx raises funding to develop TRX-4

Alantos begins phase I study with ALS 2-0426

Polyfunctional CD8+ HIV-1-specific T-cell responses seen with Remune

TNX-355 activity described in vitro and in clinical trial

GS-9137/ritonavir can be administered with zidovudine and emtricitabine/tenofovir

BTA-798 begins phase Ib study

Novel agents for treating neurological disorders disclosed in recent patent literature

Preclinical findings support the application of talnetant for schizophrenia

Novel treatment options for metabolic disorders described in recent Merck and Dainippon patents

Novel antiinfective agents disclosed in recent patent literature

TAMs get attention as drug targets

Epix and Predix complete merger

Geron report on the anti-HIV activity of their telomerase activator TAT-0002

Sirion Therapeutics completes merger with Sytera

Antisoma updates AS-1404 development progress

Novel agents for thrombotic disorders disclosed in recent Astellas patent

Further findings for Viprovex in anthrax testing

Cesamet now available for CINV

MaxCyte and Medinet collaborate on immuno-cell therapy

Marqibo studied in phase II trial for relapsed and refractory ALL

Enrollment completed in European phase III trial for LidoPAIN SP

Tindamax submitted for bacterial vaginosis

NeuroSearch cleared to begin phase IIb obesity study of tesofensine

Approvable letter for Arxxant

MedImmune files IND for MT-103

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
HX-16108 holds promise for treating inflammatory skin diseases
BioWorld Science
Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...